Compare · BNTX vs ELUT
BNTX vs ELUT
Side-by-side comparison of BioNTech SE (BNTX) and Elutia Inc. (ELUT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and ELUT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $22.99B, about 547.4x ELUT ($42.0M).
- Over the past year, BNTX is down 16.8% and ELUT is down 53.5% - BNTX leads by 36.8 points.
- BNTX has been more active in the news (3 items in the past 4 weeks vs 2 for ELUT).
- BNTX has more recent analyst coverage (25 ratings vs 0 for ELUT).
- Company
- BioNTech SE
- Elutia Inc.
- Price
- $91.56-0.03%
- $0.99+3.13%
- Market cap
- $22.99B
- $42.0M
- 1M return
- +2.30%
- +0.59%
- 1Y return
- -16.75%
- -53.52%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 3
- 2
- Recent ratings
- 25
- 0
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Latest BNTX
- SEC Form 3 filed by new insider Low-Friedrich Iris Katharina
- SEC Form 3 filed by new insider Schaffert Susanne
- The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution
- SEC Form 6-K filed by BioNTech SE
- The Multi-Billion-Dollar Search for Better Glioblastoma Treatments
- SEC Form 6-K filed by BioNTech SE
- Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
- BioNTech upgraded by UBS with a new price target
- Bernstein initiated coverage on BioNTech with a new price target
- SEC Form 6-K filed by BioNTech SE
Latest ELUT
- Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
- PRESIDENT AND CEO Mills C Randal converted options into 22,473 shares and covered exercise/tax liability with 8,064 shares, increasing direct ownership by 3% to 441,180 units (SEC Form 4) to cover taxes
- Elutia Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Director Rakin Kevin
- SEC Form 4 filed by Director Colpman David
- SEC Form 4 filed by Director Makes Brigid
- SEC Form 4 filed by Director Neels Guido J
- CHIEF SCIENTIFIC OFFICER Williams Michelle Leroux converted options into 12,500 shares and covered exercise/tax liability with 4,269 shares, increasing direct ownership by 7% to 118,052 units (SEC Form 4) (tax liability)
- CHIEF FINANCIAL OFFICER Ferguson Matthew converted options into 12,500 shares and covered exercise/tax liability with 4,485 shares, increasing direct ownership by 2% to 480,082 units (SEC Form 4) (tax withholding)
- PRESIDENT AND CEO Mills C Randal covered exercise/tax liability with 9,718 shares and converted options into 27,083 shares, increasing direct ownership by 4% to 426,771 units (SEC Form 4) (tax liability)